Emergent

The state of the hunt:

Pfizer/BioNTech asked the U.S. FDA to expand its authorization of their vaccine to adolescents.
  Numerous countries restricted the use of the AstraZeneca/Oxford shot to older people—or discontinued it altogether—even as regulators concluded the benefits outweighed the risks.
  COVAX affirmed that SII’s supply commitments to the initiative remain “legally binding” amid continued export restrictions from India.

 

Vaccines


The state of the hunt:

Pfizer and BioNTech plan to seek authorization of their vaccine for adolescents age 12-15 after promising Phase 3 results.
  J&J agreed to supply up to 400 million doses of Janssen’s jab to the African Union.
  Serum Institute of India launched clinical trials of its version of the Novavax vaccine candidate.

 

Vaccines


Approved or authorized vaccines
   
New data show lower efficacy for Pfizer/BioNTech: The…

The Journal of Clinical Investigation Tuesday published positive Phase 1 results from a U.S. National Institute of Allergy and Infectious Diseases trial showing that Maryland-based Emergent BioSolutions’ single-dose intranasal, recombinant, replicating adenovirus influenza vaccine (Ad4-H5-VTN) was safe and produced a durable immune response.

Participants who received the investigational vaccine intranasally or via tonsillar swab had significantly higher H5-specific neutralizing…

The state of the hunt:

Novavax’s protein-based vaccine candidate demonstrated 89.3% efficacy in a UK Phase 3 trial.
  J&J/Janssen’s single-dose vaccine was 66% effective against moderate to severe disease in Phase 3.
  Vaccines from J&J, Moderna, Novavax and Pfizer/BioNTech appear less effective against the SARS-CoV-2 variant first identified in South Africa.

 

Vaccines


Approved or authorized vaccines

AstraZeneca/Oxford’s…

The state of the hunt:

COVAX has inked a deal for up to 40 million doses of Pfizer/BioNTech’s vaccine.
  India launched its mass vaccination campaign against Covid-19.
  China and India are both giving away vaccine doses to their neighbors.

 

Vaccines


Approved or authorized vaccines
 
China’s Sinovac jab more effective using three-week interval: A silver lining has emerged to last week’s middling news from the Butantan Institute’s…

The state of the hunt:

WHO issued its first EUL for a Covid-19 vaccine in recent days while Britain and the EMA authorized an additional jab and China and India cleared their first shots.
  Both Bharat Biotech and Pfizer claimed their respective vaccines are effective against newly identified SARS-CoV-2 variants.
  SII pledged to sell an initial 100 million doses to India at a “special price” of $2.74 each.

 

Vaccines


Approved or authorized…

The state of the hunt:

Moderna’s and Pfizer/BioNTech’s vaccines entered 30,000-participant late-stage trials in the United States.
  Britain and the United States entered supply deals for at least 160 million doses of the GSK/Sanofi vaccine candidate.
  Gavi identified 92 LMICs eligible for its COVAX Advance Market Commitment.

 

Vaccines

Clinical trials:

Moderna reaches Phase 3: The Massachusetts-based company has begun dosing in a study of its…

The state of the hunt:

Vaccine candidates from Bharat Biotech, Medicago, Zydus Cadila and the University of Queensland entered Phase 1 or 1/2 trials this week.
  Inactivated candidates from CNBG entered Phase 3.
  India issued emergency approval of Biocon’s itolizumab for the treatment of coronavirus-related cytokine-release syndrome.

 

Vaccines

Clinical trials:

Moderna says 30,000-participant Phase 3 trials of its investigational mRNA vaccine…


The state of the hunt: 

Gavi launched an advance market commitment for Covid-19 vaccines with a $2 billion funding target. Gavi also kicked off a worldwide pooled procurement mechanism for coronavirus vaccines. CEPI announced an investment of up to $383 million in a partnership with AstraZeneca to support manufacturing of the company’s vaccine candidate for distribution by the Gavi-led procurement facility.

 

Vaccines

Existing candidates:
 
The…


The state of the hunt: 

WHO today launched the Access to COVID-19 Tools (ACT) accelerator with CEPI, Gavi, the Gates Foundation, the Global Fund, UNITAID and Wellcome Trust. The first patients were dosed yesterday in Phase 1 trials of Oxford University’s ChAdOx1 nCoV-19 vaccine candidate. Our Covid-19 Vaccine Dashboard is now live, providing comprehensive details on all candidates, including vaccine type, sponsor, grant amounts and more.

 

Vaccines

Existing…